GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma and corneal health solutions.
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
On Monday, Glaukos Corporation GKOS received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review.
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President, Investor Relations and Corporate Affairs Tom Burns - Chairman and Chief Executive Officer Joe Gilliam - President and Chief Operating Officer Conference Call Participants Tom Stephen - Stifel Richard Newitter - Truist Securities Allen Gong - JPMorgan Michael Sarcone - Jefferies Mason Carrico - Stephens Anthony Petrone - Mizuho Danielle Antalffy - UBS Operator Welcome to Glaukos Corporation's Fourth Quarter and Full-Year 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today are available at www.glaukos.com.
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.63 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings
Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
GKOS Stock Gains Following Positive Study Data on iDose Platform
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?
Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
GKOS announces New Drug Application submission for its Epioxa to the FDA.
